T1	Participants 620 794	patients with lung cancer who had been treated with myelosuppressive chemotherapy and then with subcutaneous rhG-CSF (lenograstim, 2 micrograms per kg of body weight per day)
T2	Participants 796 834	Twelve patients were randomly assigned
